Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

1. november 2026 oppdatert av: Jian Zhang,MD, Fudan University

Netupitant/Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugate Therapy in Breast Cancer: A Randomized, Multicenter, Exploratory Phase II Study

Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

84

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Jian Zhang, MD, PhD
  • Telefonnummer: 85000 +8664175590
  • E-post: syner2000@163.com

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Age ≥ 18 years. Histologically or cytologically confirmed breast cancer. Planned to initially receive one of the following antibody-drug conjugate (ADC) agents: trastuzumab deruxtecan (T-DXd), trastuzumab rezetecan (SHR-A1811), or datopotamab deruxtecan (Dato-DXd).

Planned to use netupitant/palonosetron capsules (NEPA) prophylactically as an antiemetic prior to ADC therapy.

Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Expected survival ≥ 3 months.

Adequate organ function, defined as:

Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases); Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min. Able to understand and voluntarily sign written informed consent. Able and willing to use an electronic patient-reported outcome (ePRO) device to complete daily diary records.

Exclusion Criteria:

  • Currently participating in another clinical trial that may affect the antiemetic evaluation or drug exposure of this study.

Nausea (Visual Analog Scale [VAS] ≥ 5 mm) or vomiting within 24 hours prior to enrollment.

Use of any antiemetic medication within 2 weeks prior to enrollment, including 5-HT3 receptor antagonists, NK1 receptor antagonists, glucocorticoids, metoclopramide, olanzapine, etc.

Use of benzodiazepines, opioids, or opioid-like medications within 1 week prior to enrollment or planned use during the study period (especially the Day 1-21 observation window), except single doses of midazolam, temazepam, or triazolam.

Known allergy to netupitant, palonosetron, or excipients of the NEPA capsule. Symptomatic brain metastases or leptomeningeal metastases (patients who have received treatment and been stable for ≥ 4 weeks are eligible).

Uncontrolled serious medical conditions, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), uncontrolled diabetes (HbA1c ≥ 8.0%), New York Heart Association (NYHA) functional classification ≥ III, myocardial infarction or unstable angina within 6 months, or history of clinically significant QT interval prolongation.

Psychiatric disorder or cognitive impairment that may affect the reliability of nausea/vomiting assessment or ePRO completion.

Pregnant or lactating women. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Standard (No Extended NEPA)

Standard antiemetic regimen consisting of netupitant/palonosetron (NEPA), dexamethasone, and olanzapine administered on Days 1-4 (Day 5: observation only). No extended NEPA dosing is given from Day 6 through Day 21.

Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally.

Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21.

Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21.

Eksperimentell: Extended NEPA (3 Boosts)

Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6, 11, and 16.

Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally.

Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21.

Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21.

Eksperimentell: Extended NEPA (2 Boosts)

Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6 and 13.

Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally.

Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21.

Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants with No Nausea (VAS < 5 mm) During the 120-504 Hour Window After ADC Administration
Tidsramme: 120 to 504 hours (Days 6-21) after ADC administration

The no-nausea rate, defined as the proportion of participants with a Visual Analog Scale (VAS) nausea score < 5 mm, assessed during the 120-504 hour window (Days 6-21) following ADC (trastuzumab deruxtecan, trastuzumab rezetecan [SHR-A1811], or datopotamab deruxtecan) administration.

120 to 504 hours (Days 6-21) after ADC administration

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants with No Significant Nausea (VAS < 25 mm) During the 120-504 Hour Window
Tidsramme: 120-504 hours (Days 6-21) after ADC administration

Proportion of participants with a VAS nausea score < 25 mm during the 120-504 hour window after ADC administration.

120-504 hours (Days 6-21) after ADC administration
Percentage of Participants with No Vomiting During the 120-504 Hour Window
Tidsramme: 120-504 hours (Days 6-21) after ADC administration

Proportion of participants who did not experience vomiting during the 120-504 hour window after ADC administration.

120-504 hours (Days 6-21) after ADC administration
Complete Response (CR) Rate During the 120-504 Hour Window
Tidsramme: 120-504 hours (Days 6-21) after ADC administration

Proportion of participants achieving complete response, defined as no vomiting and no use of rescue medication, during the 120-504 hour window. (Definitions per protocol.)

120-504 hours (Days 6-21) after ADC administration
Complete Protection (CP) Rate During the 120-504 Hour Window
Tidsramme: 120-504 hours (Days 6-21) after ADC administration

Proportion of participants achieving complete protection (no nausea [VAS < 5 mm], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.)

120-504 hours (Days 6-21) after ADC administration
Total Control (TC) Rate During the 120-504 Hour Window
Tidsramme: 120-504 hours (Days 6-21) after ADC administration

Proportion of participants achieving total control (no nausea [VAS = 0], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.)

120-504 hours (Days 6-21) after ADC administration
Antiemetic Efficacy Across Time Windows: No Nausea, No Significant Nausea, No Vomiting, CR, CP, TC, and Rescue Medication Rates
Tidsramme: Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)

For each of four time windows (0-24 h acute, 24-120 h delayed, 0-120 h overall, and 0-504 h full course [Day 1-21]), the following binary endpoints are assessed: no nausea rate (VAS < 5 mm), no significant nausea rate (VAS < 25 mm), no vomiting rate, complete response (CR) rate, complete protection (CP) rate, total control (TC) rate, and rescue medication use rate. The 0-120 h window reflects the period in which all three arms received identical baseline antiemetic prophylaxis (Days 1-5); by design no systematic between-arm difference is expected, and this window is used to verify the comparability of baseline efficacy and the internal consistency of the study. Missing-data handling is consistent with the primary endpoint.

Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

2. november 2026

Primær fullføring (Antatt)

1. november 2027

Studiet fullført (Antatt)

1. november 2028

Datoer for studieregistrering

Først innsendt

1. november 2026

Først innsendt som oppfylte QC-kriteriene

1. november 2026

Først lagt ut (Faktiske)

5. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere